Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
February 14 2024 - 9:18AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of February 2024 (Report No.2)
Commission File Number: 001-40303
Inspira Technologies Oxy B.H.N. Ltd.
(Translation of registrant’s name into
English)
2 Ha-Tidhar St.
Ra’anana 4366504, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form
40-F
CONTENTS
On February 14, 2024, Inspira
Technologies Oxy B.H.N. Ltd., or the Registrant, issued a press release titled “Inspira™ Receives First Ever U.S. Patent Approval
for an Orbiting Blood Oxygenation Delivery System,” a copy of which is furnished as Exhibit 99.1 with this report of foreign private
issuer on Form 6-K.
The
first, second and fourth paragraphs and the section titled “Forward-Looking Statements” in the press release are incorporated
by reference into the Registrant’s Registration Statements on Form F-3 (Registration No. 333-266748)
and Form S-8 (Registration No. 333-259057), filed with the Securities and Exchange Commission, to be a part thereof from the date
on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
Inspira Technologies Oxy B.H.N. Ltd. |
|
|
|
Date: February 14, 2024 |
By: |
/s/ Dagi Ben-Noon |
|
|
Name: |
Dagi Ben-Noon |
|
|
Title: |
Chief Executive Officer |
2
Exhibit 99.1
Inspira™
Receives First Ever U.S. Patent Approval for an Orbiting Blood Oxygenation Delivery System
94% of the Claims Were Found to be Novel
Ra’anana, Israel, February
14, 2024 – Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira
Technologies”), is a breakthrough medical technology company targeting to supersede mechanical ventilators, has received the first
ever U.S. Patent approval for an orbiting blood oxygenation delivery system, a core technology of the revolutionary INSPIRA™ ART500
device. This innovation has 16 claims found to be novel.
The orbiting blood oxygenation delivery system (VORTX™) is designed
to oxygenate blood without fiber membranes, and we believe it is expected to revolutionize the medical landscape. The current fiber technologies
used for blood oxygenation cause substantial damage to the patient’s blood cells. Unlike the natural laminar blood flow in blood vessels
inside the body, in existing fiber oxygenators, the blood is “forced” to flow in a harmful turbulent flow through many layers
of fibers while experiencing friction and shear forces within the fiber walls. Since the fiber fabric is a significant resistor to blood
flow, high-pressure differences are formed and cause significant damage to the various blood components, including, high hemolysis (breakdown
of red cells), damage to white blood cells, activation of the inflammatory system in the body, activation of the immune system, and especially
significant damage to the blood clotting system.
We believe that the orbiting blood oxygenation delivery system is another
potentially game-changing core technology of the INSPIRA ART500 device, in targeting the $19 billion mechanical ventilation market.
The INSPIRA ART500 is a breakthrough device, designed to empower breathing
in patients that are awake, by continuously measuring the patient’s blood parameters in real-time, and delivering needed oxygen
volume straight into the blood. As the INSPIRA ART500 is to be equipped with the HYLA blood sensor, it is being designed to continuously
scan the patient’s blood, potentially allowing for real-time detection of changes in patient condition and providing physicians
with decision-supportive data.
CEO of Inspira Technologies, Dagi Ben-Noon: “We believe that
this is a monumental advancement in the landscape of blood oxygenation technologies and a pivotal milestone and another key indicator
of the INSPIRA ART500’s core technological portfolio.”
Inspira Technologies OXY B.H.N. Ltd.
Inspira™ Technologies is an innovative
medical technology company in the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration
Technology (INSPIRA ART), designed to rebalance patient oxygen saturation levels. This technology potentially allows patients to
remain awake during treatment while reducing the need for highly invasive, risky, and costly mechanical ventilation systems that
require intubation and medically induced coma. The Company’s products have not yet been tested or used in humans and has not
been approved by any regulatory entity. For more information, please visit our corporate
website: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements
pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations
of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it
discusses intended benefits and uses of its technology, that its technology has the potential to revolutionize the medical landscape,
the target market for its product, the potential of its products to allow for real-time detection and the belief that the patent approval
is a monumental advancement in the landscape of blood oxygenation technologies. These forward-looking statements and their implications
are based solely on the current expectations of the Company’s management and are subject to a number of factors and uncertainties
that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required
by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and
uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s annual report on
Form 20-F for the fiscal year ended December 31, 2022 filed with the U.S. Securities and Exchange Commission (the “SEC”),
which is available on the SEC’s website, www.sec.gov
For more details:
Public Relations Manager
Adi Shmueli
Inspira Technologies
info@inspirao2.com
+972-9-9664485
MRK-ARS-086
Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD., All
rights reserved.
Inspira Technologies Oxy... (NASDAQ:IINN)
Historical Stock Chart
From Apr 2024 to May 2024
Inspira Technologies Oxy... (NASDAQ:IINN)
Historical Stock Chart
From May 2023 to May 2024